Physician profile
Piyush Patel
NPI 1356392039
$3,166.06
in general payments reported to CMS, 2019-2025
27 companies · $587 in 2025
The $587 reported for 2025 was more than what 81% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $117 · 2021: $391 · 2022: $740 · 2023: $508 · 2024: $703 · 2025: $587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,424 · Education: $374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,424.32 |
| Education | $373.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $423.01 | 2019-2023 | Krystexxa |
| Opko Pharmaceuticals, LLC | $385.85 | 2021-2025 | Rayaldee |
| Astrazeneca Pharmaceuticals LP | $229.37 | 2020-2025 | Farxiga, Lokelma |
| Novo Nordisk INC | $205.27 | 2025 | Wegovy, Ozempic |
| Vifor Pharma, INC. | $195.69 | 2022-2025 | Veltassa, Korsuva |
| Aurinia Pharma U.S., INC. | $190.03 | 2021-2023 | Lupkynis |
| Bayer Healthcare Pharmaceuticals INC. | $189.36 | 2022-2025 | |
| Travere Therapeutics, INC. | $185.83 | 2023-2025 | Filspari |
| Abbvie INC. | $136.52 | 2022 | |
| Daiichi Sankyo INC. | $125.39 | 2019-2021 | |
| Glaxosmithkline, LLC. | $124.81 | 2023-2024 | Benlysta |
| Otsuka America Pharmaceutical, INC. | $114.05 | 2021-2024 | Jynarque |
| Novartis Pharmaceuticals Corporation | $113.30 | 2022-2025 | |
| Silk Road Medical, INC. | $106.72 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter |
| Amgen INC. | $96.32 | 2022-2024 | Tavneos |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $71.87 | 2023-2024 | Tarpeyo |
| Akebia Therapeutics INC | $43.51 | 2022 | |
| Alexion Pharmaceuticals, INC. | $35.73 | 2021-2022 | |
| Scpharmaceuticals INC. | $30.04 | 2025 | |
| Ardelyx, INC. | $28.62 | 2024 | Ibsrela |
| Xeris Pharmaceuticals, INC. | $24.10 | 2022 | |
| Mallinckrodt Enterprises LLC | $22.61 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.81 | 2023 | Jardiance |
| Allergan, INC. | $18.79 | 2021 | |
| Kyowa Kirin, INC. | $17.71 | 2025 | |
| Arbor Pharmaceuticals, INC. | $17.37 | 2021 | |
| Baxter Healthcare | $13.38 | 2024 | Renal - Acute |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Piyush Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.